Mr. Timothy Whitten Joins Eleison Pharmaceuticals Board of Directors

St. Petersburg, FL, May 6, 2014 -- Eleison Pharmaceuticals LLC, a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, has announced Mr. Timothy Whitten has joined the Company's Board of Directors.

"Tim, with his deep commercialization background and his experience as CEO of a successful public biotech company, will be a great complement to our board," commented Edwin Thomas, CEO of Eleison Pharmaceuticals.

Before joining Taiho Oncology, Inc. in 2013 as Chief Commercial Officer where he currently serves, Mr. Whitten was President, CEO, and board member of Insmed, Inc. (Nasdaq: INSM). Previously, Mr. Whitten was President and CEO of Transave, Inc., and in executive positions at Pharmacyclics Inc. and Bristol-Myers Squibb Company (BMS). During his 16 years in marketing, sales and strategic planning at BMS, Mr. Whitten led the U.S. marketing group for oncology and immunology and the global marketing group for oncology, immunology and pulmonary diseases. He has been involved in several successful product launches, including leading the successful introduction of Taxol (paclitaxel) Injection, a well-known oncology product, into the U.S. market. Mr. Whitten earned his master's degree in business administration from Colgate Darden Graduate School of Business Administration at University of Virginia and received his pharmacy degree *magna cum laude* from West Virginia University.

About Eleison Pharmaceuticals

Eleison's mission is to acquire, develop, and commercialize clinical stage drug candidates for "orphan" oncology indications, providing new hope for patients with rare life-threatening diseases. The Company has two programs in late-stage development, glufosfamide and ILC, and is in discussions to acquire other promising candidates for rare cancers. Eleison was founded in 2009 and is headquartered in St. Petersburg, Florida. Additional information about Eleison can be found at our website www.eleison-pharma.com .

Glufosfamide is a third-generation alkylating agent designed for greater specificity and tumor uptake, with reduced systemic toxicities and side effects. It is currently being evaluated in a pivotal Phase 3 international randomized trial, for the second-line treatment of patients with pancreatic cancer. More than 40,000 Americans die from pancreatic cancer annually, with few therapeutic options to treat the disease and no drugs approved for second-line use.

ILC is a novel, sustained release formulation of cisplatin in a nanoscale lipid based complex administered via inhalation. ILC was designed to deliver high levels of sustained release cisplatin targeted to the lung, without systemic-related toxicities. Eleison is conducting a potentially pivotal Phase 2 trial to evaluate the safety and efficacy of ILC for the treatment of pediatric osteosarcoma. In the U.S., approximately 500 children and young adults are diagnosed with osteosarcoma each year, an often fatal bone cancer.

Forward Looking Statements

Except for statements of historical fact, the statements in this news release are forward-looking statements, including statements regarding Eleison's product candidates, their uses and potential benefits and clinical trial results and plans. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Eleison's ability to enroll and complete its current and anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, the possibility that results from these trials will not be confirmed, potential adverse side effects, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Eleison does not intend to update any forward-looking statement made in this news release.

COMPANY CONTACT: Eleison Pharmaceuticals LLC
Corporate Communications
263 13th Avenue South, Suite 375
St. Petersburg, FL 33701
tel: 215-554-3530
email: info@eleison-pharma.com